)
)
)
Pyrojas Inc.
PyrOjas Corporation is developing platforms for cancer immunotherapy and fibrotic diseases.
Please contact connect@pyrojas.com for deck and technical data.
Our Patented Platforms:
1) PyroTIMER™ – T cells that function in immunosuppressive TIMEs: overcomes T cell exhaustion, boosting CAR-T/TCR-T efficacy. Preclinical: improved infiltration/persistence/clearance.
2) PyroCells™ – Personalized Cancer Vaccines: Uses whole-tumor antigens for comprehensive responses against heterogeneity. 24hr decentralized production; advancing to trials with durable control.
3) PyroCAR™ – Safest In Vivo CAR-T cells: Lentiviral system for direct patient engineering; durable for heme/solid tumors. No CRS/ICANS
4) HiTE™ – Viral Transduction Enhancer Reagent: Boosts cell therapy manufacturing efficiency, lowers COGS 5-10x, RUO/GMP, out-licensed.
5) FibroTIDE™ – Anti-Fibrotic Recombinant Protein: Targets TGF-β for sustained effects/tissue repair. Broad use in fibrosis-driven diseases - IPF, liver fibrosis, DMD.
Address
Long Island CityNew York
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)